CAMBRIA-1 & CAMBRIA-2 phase III trials: camizestrant versus standard endocrine therapy in ER+/HER2- early breast cancer.
Erika P Hamilton, Sibylle Loibl, Thomas Bachelot...
https://pubmed.ncbi.nlm.nih.gov/40017004/Actively Recruiting
Led by AstraZeneca · Updated on 2026-10-13
4300
Participants Needed
709
Research Sites
475 weeks
Total Duration
Researchers are evaluating camizestrant compared to standard endocrine therapy in patients with ER-positive, HER2-negative early breast cancer who have an intermediate or high risk of disease recurrence. This Phase III open-label study includes patients who have completed definitive locoregional therapy, with or without chemotherapy, and have received standard adjuvant endocrine therapy for at least 2 years and up to 5 years. The study aims to determine if camizestrant improves invasive breast cancer-free survival and other important outcomes over a long-term follow-up. Participants will be randomly assigned to receive either camizestrant orally or continue standard endocrine therapy chosen by their doctor, which may include aromatase inhibitors like exemestane, letrozole, anastrozole, or tamoxifen. Treatment in both groups will last for up to 60 months. The study allows prior use of CDK46 inhibitors and includes an open-label design where both participants and researchers know the assigned treatment. During the study, participants will be monitored with assessments including survival outcomes, disease-free survival, relapse-free survival, and overall survival for up to 10 years from the last patient randomized. Safety will be tracked through adverse event reporting, laboratory and vital signs tests, and symptom questionnaires measuring arthralgia, hot flushes, vaginal dryness, and quality of life. Pharmacokinetics will be studied up to 6 months after treatment starts. The total duration of participation can extend over many years to capture long-term results.
CONDITIONS
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
A
AstraZeneca Clinical Study Information Center
A
AstraZeneca Breast Cancer Study Locator Service
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
AstraZeneca
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Camizestrant oral therapy | Standard endocrine therapy (tamoxifen, anastrozole, letrozole, or exemestane) |
|---|---|---|
| What it is | Camizestrant is an investigational, next-generation oral selective estrogen receptor degrader (SERD) being evaluated for its potential to reduce recurrence in patients with ER+/HER2- early breast cancer after at least two years of standard adjuvant endocrine therapy. | Investigator-selected standard endocrine therapy includes tamoxifen or one of three aromatase inhibitors (anastrozole, letrozole, or exemestane), given according to local practice and approved product label. |
| Role in trial | Given as the investigational therapy, tested for efficacy after previous standard adjuvant therapy in eligible patients. | Serves as the active comparator arm, representing established standard post-adjuvant endocrine therapies. |
| Primary use | Being tested for potential to further reduce breast cancer recurrence risk when given after initial years of endocrine therapy. | Used as ongoing adjuvant treatment to help prevent recurrence in hormone-receptor positive, HER2-negative early breast cancer. |
| How it is given or performed | Administered orally as a tablet, at a dose specified by the study protocol. | Tamoxifen or aromatase inhibitor (anastrozole, letrozole, or exemestane) is taken orally once daily, as per the approved product label and prescriber. |
| Evidence status | Effectiveness and safety of camizestrant in this setting are under study; results are not yet available. | The effectiveness and safety of adjuvant endocrine therapies for recurrence prevention in ER+/HER2- early breast cancer are well established, with long-term benefit shown in published studies. |
| Important limitations | Long-term safety and benefit in this setting not yet established; participation is limited to patients who have already completed at least 2 years of adjuvant endocrine therapy. | Durability of benefit and side-effect burden may vary based on individual therapy (tamoxifen or aromatase inhibitor), prior tolerance, and patient characteristics. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 60 months
Participants receive either camizestrant orally or continue standard endocrine therapy as chosen by their doctor for up to 60 months.
Regular visits as scheduled by the study team
Duration - Up to 10 years
Participants are monitored for up to 10 years after treatment to assess cancer outcomes and safety.
Periodic visits during follow-up
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Erika P Hamilton, Sibylle Loibl, Thomas Bachelot...
https://pubmed.ncbi.nlm.nih.gov/40017004/AstraZeneca
Lead Sponsor